OBJECTIVE: Multiple sources of evidence suggest that genetic factors influence variation in clinical features of schizophrenia. The authors present the first genome-wide association study (GWAS) of dimensional symptom scores among individuals with schizophrenia. METHOD: Based on the Lifetime Dimensions of Psychosis Scale ratings of 2,454 case subjects of European ancestry from the Molecular Genetics of Schizophrenia (MGS) sample, three symptom factors (positive, negative/disorganized, and mood) were identified with exploratory factor analysis. Quantitative scores for each factor from a confirmatory factor analysis were analyzed for association with 696,491 single-nucleotide polymorphisms (SNPs) using linear regression, with correction for age, sex, clinical site, and ancestry. Polygenic score analysis was carried out to determine whether case and comparison subjects in 16 Psychiatric GWAS Consortium (PGC) schizophrenia samples (excluding MGS samples) differed in scores computed by weighting their genotypes by MGS association test results for each symptom factor. RESULTS: No genome-wide significant associations were observed between SNPs and factor scores. Most of the SNPs producing the strongest evidence for association were in or near genes involved in neurodevelopment, neuroprotection, or neurotransmission, including genes playing a role in Mendelian CNS diseases, but no statistically significant effect was observed for any defined gene pathway. Finally, polygenic scores based on MGS GWAS results for the negative/disorganized factor were significantly different between case and comparison subjects in the PGC data set; for MGS subjects, negative/disorganized factor scores were correlated with polygenic scores generated using case-control GWAS results from the other PGC samples. CONCLUSIONS: The polygenic signal that has been observed in cross-sample analyses of schizophrenia GWAS data sets could be in part related to genetic effects on negative and disorganized symptoms (i.e., core features of chronic schizophrenia).
OBJECTIVE: Multiple sources of evidence suggest that genetic factors influence variation in clinical features of schizophrenia. The authors present the first genome-wide association study (GWAS) of dimensional symptom scores among individuals with schizophrenia. METHOD: Based on the Lifetime Dimensions of Psychosis Scale ratings of 2,454 case subjects of European ancestry from the Molecular Genetics of Schizophrenia (MGS) sample, three symptom factors (positive, negative/disorganized, and mood) were identified with exploratory factor analysis. Quantitative scores for each factor from a confirmatory factor analysis were analyzed for association with 696,491 single-nucleotide polymorphisms (SNPs) using linear regression, with correction for age, sex, clinical site, and ancestry. Polygenic score analysis was carried out to determine whether case and comparison subjects in 16 Psychiatric GWAS Consortium (PGC) schizophrenia samples (excluding MGS samples) differed in scores computed by weighting their genotypes by MGS association test results for each symptom factor. RESULTS: No genome-wide significant associations were observed between SNPs and factor scores. Most of the SNPs producing the strongest evidence for association were in or near genes involved in neurodevelopment, neuroprotection, or neurotransmission, including genes playing a role in Mendelian CNS diseases, but no statistically significant effect was observed for any defined gene pathway. Finally, polygenic scores based on MGS GWAS results for the negative/disorganized factor were significantly different between case and comparison subjects in the PGC data set; for MGS subjects, negative/disorganized factor scores were correlated with polygenic scores generated using case-control GWAS results from the other PGC samples. CONCLUSIONS: The polygenic signal that has been observed in cross-sample analyses of schizophrenia GWAS data sets could be in part related to genetic effects on negative and disorganized symptoms (i.e., core features of chronic schizophrenia).
Authors: Meizhang Li; Cathleen J Chang; Justin D Lathia; Li Wang; Holly L Pacenta; Anne Cotleur; Richard M Ransohoff Journal: Glia Date: 2011-01 Impact factor: 7.452
Authors: Michelle G Hamel; Joanne M Ajmo; Christopher C Leonardo; Fengrong Zuo; John D Sandy; Paul E Gottschall Journal: Exp Neurol Date: 2007-12-03 Impact factor: 5.330
Authors: Douglas F Levinson; Jubao Duan; Sang Oh; Kai Wang; Alan R Sanders; Jianxin Shi; Nancy Zhang; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Kenneth S Kendler; Robert Freedman; Frank Dudbridge; Itsik Pe'er; Hakon Hakonarson; Sarah E Bergen; Ayman H Fanous; Peter A Holmans; Pablo V Gejman Journal: Am J Psychiatry Date: 2011-02-01 Impact factor: 18.112
Authors: Hreinn Stefansson; Roel A Ophoff; Stacy Steinberg; Ole A Andreassen; Sven Cichon; Dan Rujescu; Thomas Werge; Olli P H Pietiläinen; Ole Mors; Preben B Mortensen; Engilbert Sigurdsson; Omar Gustafsson; Mette Nyegaard; Annamari Tuulio-Henriksson; Andres Ingason; Thomas Hansen; Jaana Suvisaari; Jouko Lonnqvist; Tiina Paunio; Anders D Børglum; Annette Hartmann; Anders Fink-Jensen; Merete Nordentoft; David Hougaard; Bent Norgaard-Pedersen; Yvonne Böttcher; Jes Olesen; René Breuer; Hans-Jürgen Möller; Ina Giegling; Henrik B Rasmussen; Sally Timm; Manuel Mattheisen; István Bitter; János M Réthelyi; Brynja B Magnusdottir; Thordur Sigmundsson; Pall Olason; Gisli Masson; Jeffrey R Gulcher; Magnus Haraldsson; Ragnheidur Fossdal; Thorgeir E Thorgeirsson; Unnur Thorsteinsdottir; Mirella Ruggeri; Sarah Tosato; Barbara Franke; Eric Strengman; Lambertus A Kiemeney; Ingrid Melle; Srdjan Djurovic; Lilia Abramova; Vasily Kaleda; Julio Sanjuan; Rosa de Frutos; Elvira Bramon; Evangelos Vassos; Gillian Fraser; Ulrich Ettinger; Marco Picchioni; Nicholas Walker; Timi Toulopoulou; Anna C Need; Dongliang Ge; Joeng Lim Yoon; Kevin V Shianna; Nelson B Freimer; Rita M Cantor; Robin Murray; Augustine Kong; Vera Golimbet; Angel Carracedo; Celso Arango; Javier Costas; Erik G Jönsson; Lars Terenius; Ingrid Agartz; Hannes Petursson; Markus M Nöthen; Marcella Rietschel; Paul M Matthews; Pierandrea Muglia; Leena Peltonen; David St Clair; David B Goldstein; Kari Stefansson; David A Collier Journal: Nature Date: 2009-07-01 Impact factor: 49.962
Authors: Karolina Kauppi; Lars T Westlye; Martin Tesli; Francesco Bettella; Christine L Brandt; Morten Mattingsdal; Torill Ueland; Thomas Espeseth; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Ole A Andreassen Journal: Schizophr Bull Date: 2014-11-11 Impact factor: 9.306
Authors: Alexis C Edwards; Tim B Bigdeli; Anna R Docherty; Silviu Bacanu; Donghyung Lee; Teresa R de Candia; Arden Moscati; Dawn L Thiselton; Brion S Maher; Brandon K Wormley; Dermot Walsh; Francis A O'Neill; Kenneth S Kendler; Brien P Riley; Ayman H Fanous Journal: Schizophr Bull Date: 2015-08-27 Impact factor: 9.306
Authors: Michele T Pato; Janet L Sobell; Helena Medeiros; Colony Abbott; Brooke M Sklar; Peter F Buckley; Evelyn J Bromet; Michael A Escamilla; Ayman H Fanous; Douglas S Lehrer; Fabio Macciardi; Dolores Malaspina; Steve A McCarroll; Stephen R Marder; Jennifer Moran; Christopher P Morley; Humberto Nicolini; Diana O Perkins; Shaun M Purcell; Mark H Rapaport; Pamela Sklar; Jordan W Smoller; James A Knowles; Carlos N Pato Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-05-03 Impact factor: 3.568
Authors: Anna R Docherty; Eduardo Fonseca-Pedrero; Martin Debbané; Raymond C K Chan; Richard J Linscott; Katherine G Jonas; David C Cicero; Melissa J Green; Leonard J Simms; Oliver Mason; David Watson; Ulrich Ettinger; Monika Waszczuk; Alexander Rapp; Phillip Grant; Roman Kotov; Colin G DeYoung; Camilo J Ruggero; Nicolas R Eaton; Robert F Krueger; Christopher Patrick; Christopher Hopwood; F Anthony O'Neill; David H Zald; Christopher C Conway; Daniel E Adkins; Irwin D Waldman; Jim van Os; Patrick F Sullivan; John S Anderson; Andrey A Shabalin; Scott R Sponheim; Stephan F Taylor; Rachel G Grazioplene; Silviu A Bacanu; Tim B Bigdeli; Corinna Haenschel; Dolores Malaspina; Diane C Gooding; Kristin Nicodemus; Frauke Schultze-Lutter; Neus Barrantes-Vidal; Christine Mohr; William T Carpenter; Alex S Cohen Journal: Schizophr Bull Date: 2018-10-15 Impact factor: 9.306
Authors: Catherine Do; Charles F Lang; John Lin; Huferesh Darbary; Izabela Krupska; Aulona Gaba; Lynn Petukhova; Jean-Paul Vonsattel; Mary P Gallagher; Robin S Goland; Raphael A Clynes; Andrew Dwork; John G Kral; Catherine Monk; Angela M Christiano; Benjamin Tycko Journal: Am J Hum Genet Date: 2016-05-05 Impact factor: 11.025
Authors: Amanda B Zheutlin; Adam M Chekroud; Renato Polimanti; Joel Gelernter; Fred W Sabb; Robert M Bilder; Nelson Freimer; Edythe D London; Christina M Hultman; Tyrone D Cannon Journal: Schizophr Bull Date: 2018-08-20 Impact factor: 9.306
Authors: Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff Journal: Neuropsychopharmacology Date: 2013-10-04 Impact factor: 7.853
Authors: Anna R Docherty; Andrey A Shabalin; Daniel E Adkins; Frank Mann; Robert F Krueger; Silviu-Alin Bacanu; Archie Campbell; Caroline Hayward; David J Porteous; Andrew M McIntosh; Kenneth S Kendler Journal: Schizophr Bull Date: 2020-03-27 Impact factor: 9.306